Pyridazine derivatives XIV. Study of the vasorelaxant action of 6-aryl-5-piperidino-3-hydrazinopyridazines in isolated rat thoracic aorta: Comparison with hydralazine

General Pharmacology

Volumn 30, Issue 2, 1998, Pages 201-207

  Campos Toimil, M ^a   Estevez I ^a   Ravina E ^a   Orallo, F ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Hydralazine; Hydrazinopyridazines; Intracellular activity; Rats aorta; Vasodilators

Indexed keywords

6 ARYL 5 PIPERIDINO 3 HYDRAZINOPYRIDAZINE; ANTIHYPERTENSIVE AGENT; CAFFEINE; HYDRALAZINE; NORADRENALIN; PYRIDAZINE DERIVATIVE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR ENDOTHELIUM; VASCULAR RING; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; AORTA, THORACIC; CAFFEINE; CALCIUM; HYDRALAZINE; MALE; MUSCLE CONTRACTION; NOREPINEPHRINE; PYRIDAZINES; RATS; RATS, INBRED WKY; STRUCTURE-ACTIVITY RELATIONSHIP; VASODILATOR AGENTS;

EID: 0032007888     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(97)00108-0     Document Type: Article

References (50)

1. 14C]-hydtalazine in the rat. Br. J. Pharmac. 84, 107-120.
2. Baker J. R. J., Hedwall P. R. and Hermsmeyer K. (1992) Subcellular distribution of hydralazine in rat single vascular muscle cells. Cell Biol. Int. Rep. 16, 1023-1039.
3. Bardán B. (1992) Caracterización de adrenoceptores alfa postsinápticos y estudio del mecanismo de la acción vasodilatadora de la hidralazina en la aorta de rata. Tesís Doctoral. Universidad de Santiago de Compostela.
4. Bardán B., Verde I., Moína M. J., Gil-Longo J. and Orallo F. (1989) Estudios que cuestionan la modulación por el endotelio de los efectos vasodilatadores de la hidralazina en la aorta de rata. Rev. Farmacol. Clin. Exp. 6, 251.
5. Bullock G. R., Taylor S. G. and Weston A. H. (1985) No evidence for an endothelial component in the relaxant effect of hydralazine on rat aorta. Br. J. Pharmac. 85, 269P.
6. Campos M. and Orallo F. (1996a) La hidralazina: 50 años de investigación farmacológica I. Rev. OFIL 6, 115-126.
7. Camos M. and Orallo F. (1996b) La hidralazina: 50 años de investigación farmacológica II. Rev. OFIL 6, 189-198.
8. 2+ influx in isolated aorta of normotensive (WKY) and spontaneously hypertensive rats (SHR). Can. J. Pharmac. 72(suppl, 1), 183.
9. Campos-Toimil M., Orallo F., Gil-Longo J., Verde I., Loza I. and Fernández-Alzueta A. (1994b) Pharmacological study of several effects of hydratazine in the bisected rat vas deferens. Eur. J. Pharmac. 251, 83-90.
10. Clark G. (1981) Methods for general tissue. In: Stained Procedures (4th Ed.). (Edited by Clark G.), pp. 105-310. Williams & Wilkins, Baltimore, MD.
11. Clozel M., Kuhn H. and Hefti F. (1990) Effects of angiotensin converting enzyme inhibitors and of hydralazine on endothelial function in hypertensive rats. Hypertension 16, 532-540.
12. Criscione L., Eichenberger K., Hedwall P. R. and Schmid K. (1986) Hydralazine and its metabolites: in vitro and in vivo activity in the rat. J. Cardiovosc. Pharmac. 8, 420-427.
13. Diamond J. and Janis R. A. (1978) Increases in cyclic GMP levels may not mediate relaxant effects of sodium nitroprusside, verapamil and hydralazine in rat vas deferens. Nature 271, 472-473.
14. Eleno N., Orallo F., Botana L., Espinosa J. and Cadavid I. (1987) Hydralazine-relaxing effect on rat aorta is not mediated through changes in ATPase activity. Arch. Int. Pharmacodyn. Ther. 285, 72-79.
15. 1, and hydralazine on isolated porcine coronary arteries. J. Cardiovasc. Pharmac. 23, 852-858.
16. Gil-Longo J., Laguna M. R., Verde I., Castro M. E., Orallo F., Fontenla J. A., Calleja J. M., Raviña E. and Terán C. (1993) Pyridazine derivatives XI: antihypertensive activity of 3-hydrazinocycloheptyl [1,2-c] pyridazine and its hydrazone derivatives. J. Pharm. Sci. 82, 286-290.
17. Gil-Longo J., Orallo F., Verde I., Campos M. and Calleja J. M. (1992) Role of the endothelial system in BAY K 8644 enantiomer and nifedipine vasomodulator action in rat aorta. Eur. J. Pharmac. 221, 1-8.
18. Gurney A. M. (1994) Mechanisms of drug-induced vasodilation. J. Pharm. Pharmac. 46, 242-251.
19. Gurney A. M. and Allam M. (1995) Inhibition of calcium release from the sarcoplasmic reticulum of rabbit aorta by hydralazine. Br. J. Pharmac. 114, 238-244.
20. Hasegawa T. and Song C. H. W. (1991) Effect of hydralazine on the blood flow in tumors and normal tissues in rats. Int. J. Radiat. Oncol. Biol. Phys. 20, 1001-1007.
21. Hersmeyer K., Trapani A., Abel P. W. and Worcel M. (1983) Effect of hydralazine on tension and membrane potential in the rat caudal artery, J. Pharmac. Exp. Ther. 227, 322-326.
22. Horsman M. R., Nordsmark M., Hoyer M. and Overgaard J. (1995) Direct evidence that hydralazine can induce hypoxia in both transplanted and spontaneous murine tumours. Br. J. Cancer 72, 1474-1478.
23. Jacobs M. (1984) Mechanism of action of hydralazine on vascular smooth muscle. Biochem. Pharmac. 33, 2915-2919.
24. Karaki H. and Weiss G. B. (1988) Calcium release in smooth muscle. Life Sci. 42, 111-122.
25. Kauffman R. F., Schenck K. W., Conery B. G. and Cohen M. L. (1986) Effects of pinacidil on serotonin-induced contractions and cyclic nucleotide levels in isolated rat aortae: comparison with nitroglycerin, minoxidil, and hydralazine. J. Cardiovasc. Pharmac. 8, 1195-1200.
26. Khayyal M., Gross F. and Kreye V. A. W. (1981) Studies on the direct vasodilator effect of hydralazine in the isolated rabbit renal artery. J. Pharmac. Exp. Ther. 216, 390-394.
27. Koch P., Wilffert B., Wilhelm D. and Peters T. (1990) An approach to differentiate between noradrenaline-elicited contractile processes in the rat isolated aorta. Naunyn Schmiedeberg's Arch. Pharmac. 342, 454-461.
28. Kruszyna H., Kruszyna R., Smith R. P. and Wilcox D. E. (1987) Red blood cells generate nitric oxide from directly acting, nitrogenous vasodilators. Toxicol. Appl. Pharmac. 91, 429-438.
29. Lipe S. and Moulds R. F. W. (1981) In vitro differences between human arteries and veins in their responses to hydralazine. J. Pharmac. Exp. Ther. 217, 204-208.
30. Matsui K., Ogawa Y. and Imai S. (1994) Relaxant effects of pinacidil, nicorandil, hydralazine and nifedipine as studied in the porcine coronary artery and guinea-pig taenia coli. Arch. Int. Pharmacodyn. Ther. 283, 124-133.
31. McLean A. J., DuSouich P., Barron K., Carrier O., Haegele K. D. and McNay J. L. (1978) Study of in vitro effects of hydralazine metabolites. Comparative evaluation of products of hydroxylation, hydrolysis and conjugation. Arch. Int. Pharmacodyn. Ther. 235, 19-25.
32. 2-adrenoceptor agonists in isolated rubbed rat aorta. Gen. Pharmac. 25, 165-172.
33. 1-adrenoceptors in vascular smooth muscle. Br. J. Pharmac. 99, 197-201.
34. Nelson M. T., Patlak J. B., Worley J. F. and Standen N. B. (1990) Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. Am. J. Physiol. 259, C3-C18.
35. Nishizuka Y. (1984) The role of protein kinase C in cell surface signal transduction and tumor promotion. Nature 308, 693-698.
36. Noguera M. A. and D'Ocón M. P. (1992) Different and common intracellular calcium-stores mobilized by noradrenaline and caffeine in vascular smooth muscle. Naunyn Schmiedebergs Arch. Pharmac. 345, 333-341.
37. Noguera M. A. and D'Ocón M. P. (1993) Participation of intracellular calcium stores in serotonin-induced contractions in rat aorta. Pharmacology 47, 145-151.
38. Orallo F. (1996) Regulation of cytosolic calcium levels in vascular smooth muscle. Pharmac. Ther. 69, 153-171.
39. Orallo F., Fontenla J. A. and Calleja J. M. (1990) Diferente sensibilidad de la aorta de ratas normotensas y genéticamente hipertensas (SHR) a la acción de la hidralazina. Comparación con sus efectos cardiovasculares "in vivo." Eur. Rev. Med. Pharmac. Sci. 12, 211-216.
40. 45Ca influx of rat aorta. J. Pharm. Pharmac. 43, 356-359.
41. Polson J. B. and Strada S. J. (1996) Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu. Rev. Pharmac. Toxicol. 36, 403-427.
42. Quast U. (1992) Potassium channel openers: pharmacological and clinical aspects. Fundam. Clin. Pharmac. 6, 279-293.
43. Raviña E., Terán C., Domínguez N. G., Masaguer C. F., Gil-Longo J., Orallo F. and Calleja J. M. (1991) Pyridazine derivatives VIII: Synthesis and antihypertensive activity of 6-(2-thienyl)-5-aminomethyl-3-hydrazinopyridazines. Arch. Pharm. (Weinheim) 324, 455-459.
44. Shepherd A. M. M., Haegele K. D., Ludden T. M., Talseth T., Clementi W. A. N. and McNay J. L. (1979) Hydralazine disposition following a single oral dose in human volunteers. Clin. Res. 27, 318.
45. Sorrentino V. and Volpe P. (1993) Ryanodine receptors: how many, where and why? Trends Pharmac. Sci. 14, 98-103.
46. Spokas E. G., Folco G., Quilley J., Chander P. and McGiff J. C. (1983) Endothelial mechanism in the vascular action of hydralazine. Hypertension 5, I-107-I-111.
47. Sunahara R. K., Dessauer C. W. and Gilman A. G. (1996) Complexity and diversity of mammalian adenylyl cyclases. Annu. Rev. Pharmac. Toxicol. 36, 461-480.
48. von der Weid P. Y., Serebryakov V. N., Orallo F., Bergmann C., Snetkov V. A. and Takeda K. (1993) Effects of ATP on cultured smooth muscle cells from rat aorta. Br. J. Pharmac. 108, 638-645.
49. 45Ca in rabbit aortic smooth muscle. Blood Vessels 18, 230.
50. Yen M. H., Wu C. C., Chiou W. F. and Liao C. H. (1989) Effects of hydralazine on guanosine cyclic 3′,5′-monophosphate levels in rat aorta. Proc. Natl. Sci. Council Repub. China [B] 13, 83-88.